Study of telitacicept for children with IgA kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if telitacicept can safely help children aged 5–18 with IgA nephropathy or IgA vasculitis nephritis. It aims to reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 5 and 18 years old
- You weigh at least 25 kg (about 55 pounds)
- You have been diagnosed with IgA nephropathy or IgA vasculitis nephritis
- You have moderate to high protein in your urine
- Your kidney function is at least 30% of normal, based on a formula using your height and blood test
- You do not have any active infections or other serious medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted medication called Telitacicept for children and teens with kidney inflammation caused by IgA vasculitis. It aims to reduce protein in the urine and protect kidney function.
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
This study looks at the long-term safety and effectiveness of atacicept in people with IgA nephropathy (IgAN) who have already completed treatment in a previous atacicept study. It is for patients who want to continue their care and see how well the medicine works over more time.
This trial tests a universal cell therapy called GT719 that targets CD19 on B cells to treat several immune-mediated kidney diseases, including IgA nephropathy, ANCA vasculitis, membranous nephropathy, and others. It may help people who have not responded well to standard treatments.
This trial tests telitacicept in people with IgA nephropathy that has not responded well to standard care. It aims to reduce harmful kidney inflammation and protein leakage in the urine.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.